Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
There is no primary hypothesis to be tested for this study.
|
national trial reference number | NCT05853367 |
|
Conditions |
Advanced Solid Tumors, Metastatic Solid Tumors
|
|
Age Range | 18+ |
|
Sex | All |
|
Current trial phase | 1 |
|
Trial start and end dates |
07-06-2023 02-12-2028 |
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.